Table 1 Percent growth inhibition of cells in response to HER-targeted therapies
From: β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib
Cell line | Drug → | Lapatinib | Trastuzumab | LT |
|---|---|---|---|---|
Derivative | % Inhibition (95% CI) | % Inhibition (95% CI) | % Inhibition (95% CI) | |
BT474 | Parental | 100.0% | 72.1% (67.6%, 76.0%) | 100.0% |
Resistant | 5.7% (-0.3%, 11.4%) | 11.4% (5.8%, 16.8%) | 13.7% (8.6%, 18.6%) | |
HCC1954 | Parental | --- | 7.4% (3.8%, 10.9%) | 100.0% |
Resistant | --- | 5.4% (1.4%, 9.2%) | 37.8% (32.5%, 42.7%) |